Sustained Release of Exendin 4 Using Injectable and Ionic-Nano-Complex Forming Polymer Hydrogel System for Long-Term Treatment of Type 2 Diabetes Mellitus

ACS Appl Mater Interfaces. 2019 May 1;11(17):15201-15211. doi: 10.1021/acsami.8b19669. Epub 2019 Apr 18.

Abstract

Daily treatment of diabetes to stabilize blood glucose level poses a challenge for patients with diabetes mellitus. Diabetes is a long-term metabolic disorder, and the treatment lasts for the rest of the patient's life after diagnosis. We presented a new injectable hydrogel depot system using exendin 4 (Ex-4) interactive and complex forming polymeric ionic-nano-particles for long-term antidiabetes treatment. Protamine-conjugated polymer (ProCP) was developed to form ionic-nano-complexes with Ex-4, as the amino-group-rich protamine and the negatively charged Ex-4 ( pI: 4.86) interact with each other due to their opposite electric charges in physiological conditions. Morphologically, the ProCP were nanoparticles in aqueous condition (10 wt % of ProCP in phosphate-buffered solution, <25 °C) and formed condensed ionic- and nano-complexes with Ex-4. The complexes formed a bulk hydrogel when exposed to body temperature. A slow release of the Ex-4/ProCP ionic-nano-complexes occurred from the hydrogel depot, followed by Ex-4 dissociation from the ionic-nano-complexes and hydrolysis of ProCP. Given that the Ex-4 release occurs after the complex releases from the hydrogel, the periods of Ex-4 release and hydrogel maintenance may be similar. The present system showed a considerably prolonged Ex-4 release. Additionally, it showed potential as a long-term effective and reproducible antidiabetes treatment.

Keywords: diabetes mellitus; exenatide; injectable hydrogel; ionic complex; sustained release.

MeSH terms

  • Animals
  • Cell Survival / drug effects
  • Delayed-Action Preparations
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / veterinary
  • Exenatide / chemistry*
  • Exenatide / pharmacokinetics
  • Exenatide / therapeutic use
  • Half-Life
  • Hydrogels / chemistry*
  • Hypoglycemic Agents / chemistry*
  • Hypoglycemic Agents / pharmacokinetics
  • Hypoglycemic Agents / therapeutic use
  • Injections, Subcutaneous
  • Ions / chemistry
  • Male
  • Mice
  • Mice, Nude
  • NIH 3T3 Cells
  • Nanostructures / chemistry*
  • Optical Imaging
  • Polymers / chemistry*
  • Polymers / toxicity
  • Protamines / chemistry
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Delayed-Action Preparations
  • Hydrogels
  • Hypoglycemic Agents
  • Ions
  • Polymers
  • Protamines
  • Exenatide